Charles River Laboratories And Captain T Cell Announce Plasmid DNA And Retrovirus Vector Production Agreement; Captain T Cell To Utilize Charles River's CGT Accelerator Program For Phase I Clinical Trial Of TCR-T Cell Therapy For Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories and Captain T Cell have announced an agreement for the production of plasmid DNA and retrovirus vectors. Captain T Cell will use Charles River's CGT Accelerator Program for a Phase I clinical trial of TCR-T cell therapy targeting solid tumors.
June 17, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River Laboratories has entered into a partnership with Captain T Cell for the production of plasmid DNA and retrovirus vectors. This collaboration will leverage CRL's CGT Accelerator Program for a Phase I clinical trial of TCR-T cell therapy for solid tumors.
The partnership with Captain T Cell and the use of CRL's CGT Accelerator Program for a Phase I clinical trial is likely to positively impact Charles River Laboratories. This collaboration highlights CRL's capabilities in the biotech sector and could lead to future growth opportunities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80